UPS (NYSE Code: UPS) is expanding its pharmaceutical products through the establishment of UPS cold chain solutions, a complete set of cold chain technologies, first-class capabilities and new and expanded global facilities to provide complete, end-to-end end temperature control logistics.Wes Wheeler said: "For many years, our customers have been taking advantage of our cold chain capabilities, but the pandemic has made UPS take faster action to strengthen an integrated cold chain solution to support the future of the pharmaceutical and medical device industry," the president of UPS Healthcare. "UPS's nearly perfect and timely delivery of COVID-19 vaccine proves that our network can effectively and efficiently process bio-derived drugs even under extreme temperatures."Chronic and life-threatening diseases, including respiratory system, autoimmune and cardiovascular diseases, are the fastest-growing disease categories in the world, promoting the rapid development of bio-derived temperature control drugs and therapies. According to Biopharma Cold Chain Sourcebook, the cold chain trend shows that between 2018 and 2024, the cold chain trend of drugs that need to be stored and transported at least 2 to 8 degrees Celsius will increase by 48%. In addition, the overall market of cold chain services (packaging, transportation and data services) is expected to significantly accelerate growth in the next three years, with a growth rate of 24% by 2024 after a 10% increase from 2019 to 202
Kate Gutmann, UPS Sales and Solutions Officer and Vice President of UPS Global Healthcare * *, said: "The future of the healthcare and pharmaceutical industry will increasingly rely on a strong cold-chain network to safely provide customers with temperature-control drugs and therapies." The continuous development of our cold-chain products ensures that UPS is ready for the future and can continue to provide long-term value to our healthcare customers. Manage end-to-end temperature offsets，UPS Cold Chain Solutions aims to provide pharmaceutical companies, healthcare providers and laboratories with complete end-to-end cold chain services, including storage and distribution, transportation, visibility and capabilities, to meet their complex needs for key products. Products are all over the world.As part of the continuous and active strategy to build the complex capacity of cold chain logistics, UPS Healthcare is expanding and enhancing its temperature control products and services, including:Cold chain GMP storage capacity - about 390000 square feet of coolers and freezers are installed in UPS facilities to support the storage of biological agents from 2 ℃ to minus 80 ℃Packaging customization - recommendations for specific temperature-controlled packaging options to minimize total cost while ensuring safe and efficient transportation of products
UPS 欧洲冷链地面网络扩展——增加更多地面运输车队，加强网关和专家团队之间的联系，以创建满足客户需求的可定制解决方案
运输效率 – 通过空运或海运提供四种灵活的温度调节服务选项，可进行配置以满足药品包装的需求并帮助降低客户成本
使用UPS® Premier技术进行监控- 协议可在 UPS 网络中的任何位置对其位置 10 英尺内的有盖托盘、箱子、拖车和包裹提供可见性
设施更新——在意大利和澳大利亚建设两个符合 GDP 标准、获得医疗保健许可的新设施，以及对荷兰、捷克、波兰、匈牙利和美国设施的扩建和冷链改造项目
“UPS 为的冷链交付和物流设定了很高的标准，这些当前和未来对创新解决方案的投资将确保我们不断提高标准，”惠勒说。“对于我们的客户，我们将继续专注于兑现我们对‘以质量为中心’的承诺。患者驱动。”